Prevention of Urinary Stones With Hydration



Status:Recruiting
Conditions:Nephrology
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:12 - Any
Updated:3/16/2019
Start Date:September 13, 2017
End Date:September 1, 2021
Contact:Laura Johnson
Email:laura.m.johnson@duke.edu
Phone:919-323-6831

Use our guide to learn which trials are right for you!

A randomized clinical trial to investigate the impact of increased fluid intake and increased
urine output on the recurrence rate of urinary stone disease (USD) in adults and children.
The primary aim of the trial is to determine whether a multi‐component program of behavioral
interventions to increase fluid intake will result in reduced risk of stone disease
progression over a 2‐year period.

This is a two arm randomized controlled trial that incorporates pragmatic features, an
adaptable intervention, patient choice, and remote monitoring of fluid intake through a
"smart" water bottle. The study period is 24 months and will enroll approximately 1642
participants. Randomization will be stratified within a study site by age (adult vs.
adolescent) and first time vs. recurrent stone former.

Intervention and control arm study participants will receive a smart water bottle that
records daily fluid consumption, usual care including guideline-based recommendations of
adequate fluid intake to decrease kidney stone recurrence, and periodic 24 hour urine
collections, imaging (low-dose CT scan or ultrasound) and follow-up questionnaires.

Inclusion Criteria:

1. Aged ≥ 12 years

2. At least 1 symptomatic stone event (passage or procedural intervention) within 3 years
prior to enrollment or a symptomatic stone event within 5 years if the patient also
has new stone formation detected on imaging during the last 5 years. Symptomatic stone
defined as any of the following:

1. Stone passage

2. Procedural intervention

3. Radiographically or ultrasonographically confirmed stone with any of the
following:

i. Gross hematuria

ii. Renal colic or atypical abdominal pain attributed to the stone, as determined by a
treating provider

iii. A clinical pattern of intermittent symptoms consistent with intermittent
obstruction at the ureteropelvic junction, as determined by a treating provider

3. Low 24‐hr urine volume

1. ≥18 years old: <1.8 L/day

2. <18 years old: <20 ml/Kg/day up to 1.8L/day

4. Able to provide informed consent (parental permission for children)

5. Owning and willing to use a smartphone or other device (e.g., tablet) compatible with
the study‐provided wireless enabled "smart" bottle

Exclusion Criteria:

1. Spinal cord injury

2. Currently undergoing active treatment for cancer except basal cell skin cancer, or
patients with a history of cancer who completed their initial therapy <1 year before
screening.

3. Known infectious (struvite), monogenic or other causes of stone disease for which
therapies are likely to significantly alter course of stone disease

1. Cystinuria

2. Primary hyperoxaluria

3. Primary xanthinuria

4. Primary hyperparathyroidism

5. Sarcoidosis

6. Medullary sponge kidney

4. History or presence of hyponatremia (serum sodium <130 mmol/L) or hypo‐osmolality
(serum osmolality <275 mosm/kg)

5. Study participants with comorbidities that preclude high fluid intake or prior surgery
precluding high fluid intake or leading to GI fluid losses

1. History of or current Crohn's disease, ulcerative colitis, short gut syndrome
(e.g. ileostomy, bowel bypass surgery to treat obesity, small bowel resection),
chronic diarrhea, or GI tract ostomy.

2. History of malabsorptive (e.g., Roux‐en‐Y gastric bypass) or restrictive (e.g.,
sleeve gastrectomy) bariatric surgery procedures

3. Congestive heart failure

i. NYHA class II or greater, and/or ii. Hospital admission in the past year for heart
failure d. Lung disease with a home oxygen requirement e. Chronic kidney disease (eGFR
<30 ml/min/1.7 m2 over a 3‐month period) i. For adults (age ≥18), we will use the
CKD‐Epi equation which requires the measurement of serum creatinine only. ii. For
children (age <18), we will use the bedside Schwartz (CKiD) formula. f. Nephrotic
syndrome (>3.5 grams of protein per 24 hours) g. Cirrhosis with ascites

6. Women who are currently pregnant or planning pregnancy within 2 years.

7. Renal transplant recipient

8. Bedridden study participants (ECOG ≥ 3)

9. Uncorrected anatomical obstruction of the urinary tract

10. History of recurrent urinary tract infections (> 3 UTI/year proven by urine culture)

11. Exclusions due to medication use:

1. Chronic use of lithium

2. Long‐term glucocorticoid use (> 7.5 mg prednisone daily for > 30 days prior to
enrollment)

3. Intake of narcotic medication on a daily basis for >30 days prior to enrollment

4. Supplemental Vitamin C (> 1 g daily)

12. Individuals with stones that have developed after the initiation of medications that
are strongly associated with USD such as carbonic anhydrase inhibitors (acetazolamide,
topiramate, zonisamide), high dose vitamin C (> 1 g daily), high dose calcium
supplementation (> 1,200 mg daily) AND who have discontinued or plan to discontinue
these medications.

13. Individuals with stones composed of medications that may crystallize in the urine
(guaifenesin, sulfonamides, triamterene, and the protease inhibitors indinavir and
nelfinavir) AND who have discontinued or plan to discontinue these medications.

Note: Individuals who are on long‐term medications that increase the risk of stone
disease, who cannot stop these medications due to other chronic conditions (e.g., HIV)
and who may reduce their risk for stone recurrence through increased fluid intake,
will be eligible to participate in the trial. Examples of these medications include:

1. Carbonic anhydrase inhibitors (acetazolamide, topiramate, zonisamide)

2. Medications that may crystallize in the urine (guaifenesin, sulfonamides,
triamterene, and the protease inhibitors indinavir and nelfinavir).

14. Study participants <2 yrs life expectancy

15. Non‐English Speakers

16. History of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

17. Anatomical urologic abnormalities including ileal conduits, horseshoe kidney,
megaureter or solitary kidney.

18. Psychiatric conditions impairing compliance with the study

19. Vulnerable population (prisoner and/or cognitive impairment that the investigator
feels will impact the study participant's ability to participate in the protocol)

20. Individual who will be unable to participate in the protocol in the judgment of the
investigator.
We found this trial at
8
sites
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Sriharan Sivalingam, MD, MSc, FRCSC
Phone: 216-444-0124
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Gregory Tasian, MD, MSc, MSCE
Phone: 267-426-1337
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Principal Investigator: Jonathan Harper, MD
Phone: 206-616-5170
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Naim Maalouf, MD
Phone: 214-645-8787
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1935 Medical District Drive
Dallas, Texas 75390
Principal Investigator: Naim Maalouf, MD
Phone: 214-456-0279
?
mi
from
Dallas, TX
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Peter Reese, MD, MSCE
Phone: 215-573-8070
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: John Lieske, MD
Phone: 507-538-2902
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Henry Lai, MD
Phone: 314-362-8045
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials